Evidence map›Paper›PMID 42365201›Full record

ArticleCommunications biology2026

SMPD3 suppresses oligodendroglioma growth via dual autocrine-paracrine roles.

Fermisk Saleh, Anjali Balakrishnan, Lata Adnani, Shiekh Tanveer Ahmad, Vorapin Chinchalongporn, Ahmed El-Sehemy, Thomas Olender, Myra J Chen, Aditya Kshirsagar, Andrew Kennedy and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Fermisk SalehSunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1585-8830
Anjali BalakrishnanSunnybrook Research Institute, Toronto, ON, Canada.
Lata AdnaniSunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2852-6915
Shiekh Tanveer AhmadCenter of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Vorapin ChinchalongpornSunnybrook Research Institute, Toronto, ON, Canada.
Ahmed El-SehemyDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Thomas OlenderOttawa Hospital Research Institute, Ottawa, ON, Canada.
Myra J ChenDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Aditya KshirsagarDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8926-9353
Andrew KennedySunnybrook Research Institute, Toronto, ON, Canada.
Nilakshi KulathungaSunnybrook Research Institute, Toronto, ON, Canada.
Oleksandr ProkopchukSunnybrook Research Institute, Toronto, ON, Canada.
Lakshmy VasanSunnybrook Research Institute, Toronto, ON, Canada.
Yacine TouahriSunnybrook Research Institute, Toronto, ON, Canada.
Rehnuma IslamInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.
Sajeevan SujanthanSunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-3128-3977
Dawn ZinykSunnybrook Research Institute, Toronto, ON, Canada.
Lacrimioara C ComanitaDonald K. Johnson Eye Institute, University Health Network Research Institute, Toronto, ON, Canada.
Boris KanSunnybrook Research Institute, Toronto, ON, Canada.
Taylor FlemingSunnybrook Research Institute, Toronto, ON, Canada.
Iacovos P MichaelSunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7674-1233
Cindi M MorsheadDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada.
Hon S LeongSunnybrook Research Institute, Toronto, ON, Canada.
Satoshi OkawaPittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Marjorie BrandOttawa Hospital Research Institute, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0001-8915-8012
Valerie A WallaceDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Jennifer A ChanDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0001-9798-1551
Carol SchuurmansSunnybrook Research Institute, Toronto, ON, Canada. cschuurm@sri.utoronto.ca.ORCID http://orcid.org/0000-0003-3567-0058

Funding

Canada First Research Excellence Fund (Fonds d'excellence en recherche Apogée Canada) cycle 2Cancer Research Society (Société de Recherche sur le Cancer) 20159International Development Research Centre (Centre de recherches pour le développement international) 108875Terry Fox Research Institute (Institut de Recherche Terry Fox) PPG #1124
6 · The paper itself

Abstract

Oligodendrogliomas (ODGs) are slow-growing tumors with poorly defined biology. Here, we identify SMPD3, encoding neutral sphingomyelinase 2 (nSMase2), as a negative regulator of ODG progression via extracellular vesicle (EV) biogenesis and autocrine-paracrine signaling. High SMPD3 expression correlates with longer survival in ODG and low-grade glioma patients. SMPD3 knockdown in patient-derived BT54 and BT88 cells increases proliferation, enhances BT88 invasion in cerebral organoids, and accelerates BT88-tumor growth in mouse xenografts and chick CAM assays. Patient tumors display abnormal non-neoplastic glial proliferation and a ribosome-rich transcriptional signature in tumor-associated oligodendrocytes. Concordantly, ODG-derived EVs, enriched in ribosomal proteins, suppress astrocyte proliferation. Pharmacological inhibition of nSMase2 (GW4869) or ribosome biogenesis (Rbin1, diazaborine) increases ODG cell proliferation while reducing protein synthesis. Blocking EV synthesis amplifies ribosome inhibition effects, whereas exogenous EVs attenuate them. Thus, SMPD3-mediated EV signaling and ribosomal stress converge to regulate ODG proliferation, establishing SMPD3 as a key regulator and potential therapeutic target.

Indexed as

Autocrine CommunicationBrain NeoplasmsOligodendrogliomaParacrine CommunicationSphingomyelin PhosphodiesteraseAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceSphingomyelin Phosphodiesterase

Identifiers

PMID42365201
PMCPMC13677728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.